Putting huntingtin "aggregation" in view with windows into the cellular milieu

Current Topics in Medicinal Chemistry

Volumn 12, Issue 22, 2012, Pages 2611-2622

  Hatters, Danny M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aggregation; Huntingtin; Huntington's disease (HD); Misfolding; Polyglutamine (polyQ)

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HEAT SHOCK PROTEIN 70; HUNTINGTIN; POLYGLUTAMINE;

AGAR GEL ELECTROPHORESIS; ATOMIC FORCE MICROSCOPY; CELL INCLUSION; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; TOXICITY; TRANSMISSION ELECTRON MICROSCOPY;

AMINO ACID SEQUENCE; ANTIBODIES; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PEPTIDES; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84874872486     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212220013     Document Type: Review

References (154)

1. Duyao, M.; Ambrose, C; Myers, R.; Novelletto, A.; Persichetti, F.; Frontali, M.; Folstein, S.; Ross, C; Franz, M.; Abbott, M.; Gray, J.; Conneally, P.; Young, A.; Penney, J.; Hollingsworth, Z.; Shoulson, I.; Lazzarini, A.; Falek, A.; Koroshetz, W.; Sax, D.; Bird, E.; Vonsattel, J.; Bonilla, E.; Alvir, J.; Bickham Conde, J.; Cha, J. H.; Dure, L.; Gomez, F.; Ramos, M.; Sanchez-Ramos, J.; Snodgrass, S.; de Young, M.; Wexler, N.; Moscowitz, C; Penchaszadeh, G.; MacFarlane, H.; Anderson, M.; Jenkins, B.; Srinidhi, J.; Barnes, G.; Gusella, J.; MacDonald, M., Trinucleotide Repeat Length Instability and Age of Onset in Huntington's Disease. Nat. Genet., 1993, 4 (4), 387.
2. Nance, M. A.; Myers, R. H., Juvenile onset Huntington's disease-clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev., 2001, 7 (3), 153-157.
3. MacDonald, M. E.; Ambrose, C. M.; Duyao, M. P.; Myers, R. H.; Lin, C; Srinidhi, L.; Barnes, G.; Taylor, S. A.; James, M.; Groot, N.; MacFarlane, H.; Jenkins, B.; Anderson, M. A.; Wexler, N. S.; Gusella, J. F.; Bates, G. P.; Baxendale, S.; Hummerich, H.; Kirby, S.; North, M.; Youngman, S.; Mott, R.; Zehetner, G.; Sedlacek, Z.; Poustka, A.; Frischauf, A.-M.; Lehrach, H.; Buckler, A. J.; Church, D.; Doucette-Stamm, L.; O'Donovan, M. C; Riba-Ramirez, L.; Shah, M.; Stanton, V. P.; Strobel, S. A.; Draths, K. M.; Wales, J. L.; Dervan, P.; Housman, D. E.; Altherr, M.; Shiang, R.; Thompson, L.; Fielder, T.; Wasmuth, J. J.; Tagle, D.; Valdes, J.; Elmer, L.; Allard, M.; Castilla, L.; Swaroop, M.; Blanchard, K.; Collins, F. S.; Snell, R.; Holloway, T.; Gillespie, K.; Datson, N.; Shaw, D.; Harper, P. S., A Novel Gene Containing a Trinucleotide Repeat that is Expanded and Unstable on Huntington's Disease Chromosomes. Cell, 1993, 72 (6), 971-983.
4. DiFiglia, M.; Sapp, E.; Chase, K. O.; Davies, S. W.; Bates, G. P.; Vonsattel, J. P.; Aronin, N., Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain. Science, 1997, 277 (5334), 1990-1993.
5. Gutekunst, C.-A.; Li, S.-H.; Yi, H.; Mulroy, J. S.; Kuemmerle, S.; Jones, R.; Rye, D.; Ferrante, R. J.; Hersch, S. M.; Li, X.-J., Nuclear and Neuropil Aggregates in Huntington's Disease: Relationship to Neuropathology. J. Neurosci., 1999, 19 (7), 2522-2534.
6. Moffitt, H.; McPhail, G. D.; Woodman, B.; Hobbs, C; Bates, G. P., Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS ONE, 2009, 4 (11), e8025.
7. Sikorski, P.; Atkins, E., New Model for Crystalline Polyglutamine Assemblies and Their Connection with Amyloid Fibrils. Biomacromolecules, 2004, 6 (1), 425-432.
8. Sharma, D.; Shinchuk, L. M.; Inouye, H.; Wetzel, R.; Kirschner, D. A., Polyglutamine homopolymers having 8-45 residues form slablike p-crystallite assemblies. Proteins, 2005, 61 (2), 398-411.
9. Robertson, A. L.; Bottomley, S. P., Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr. Med. Chem., 2010, 17 (27), 3058-3068.
10. Chiti, F.; Dobson, C. M., Protein Misfolding, Functional Amyloid, and Human Disease. Ann. Rev. Biochem., 2006, 75 (1), 333-366.
11. Hodgson, J. G.; Agopyan, N.; Gutekunst, C.-A.; Leavitt, B. R; LePiane, F.; Singaraja, R.; Smith, D. J.; Bissada, N.; McCutcheon, K.; Nasir, J.; Jamot, L.; Li, X.-J.; Stevens, M. E.; Rosemond, E.; Roder, J. C; Phillips, A. G.; Rubin, E. M.; Hersch, S. M.; Hayden, M. R., A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration. Neuron, 1999, 23 (1), 181-192.
12. Kuemmerle, S.; Gutekunst, C.-A.; Klein, A. M.; Li, X.-J.; Li, S.-H.; Beal, M. F.; Hersch, S. M.; Ferrante, R. J., Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol, 1999, 46 (6), 842-849.
13. Li, L.-B.; Bonini, N. M., Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci., 2010, 33 (6), 292-298.
14. Krzyzosiak, W. J.; Sobczak, K.; Wojciechowska, M.; Fiszer, A.; Mykowska, A.; Kozlowski, P., Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res., 2012, 40 (1), 11-26.
15. Zu, T.; Gibbens, B.; Doty, N. S.; Gomes-Pereira, M.; Huguet, A.; Stone, M. D.; Margolis, J.; Peterson, M.; Markowski, T. W.; Ingram, M. A. C; Nan, Z.; Forster, C; Low, W. C; Schoser, B.; Somia, N. V.; Clark, H. B.; Schmechel, S.; Bitterman, P. B.; Gourdon, G.; Swanson, M. S.; Moseley, M.; Ranum, L. P. W., Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. USA, 2011, 108 (1), 260-265.
16. Sipe, J. D.; Benson, M. D.; Buxbaum, J. N.; Ikeda, S.-I.; Merlini, G.; Saraiva, M. J. M.; Westermark, P., Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid, 2010, 17 (3-4), 101-104.
17. Kelly, J. W., The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol., 1998, 8 (1), 101-106.
18. Dobson, C. M., Protein Folding and Misfolding. Nature, 2003, 426 (6968), 884-890.
19. Scherzinger, E.; Sittler, A.; Schweiger, K.; Heiser, V.; Lurz, R.; Hasenbank, R.; Bates, G. P.; Lehrach, H.; Wanker, E. E., Self-assembly of Polyglutamine-containing Huntingtin Fragments into Amyloid-like Fibrils: Implications for Huntington's Disease Pathology. Proc. Natl. Acad. Sci. USA, 1999, 96 (8), 4604-4609.
20. Hatters, D. M., Protein Misfolding Inside Cells: The Case of Huntingtin and Huntington's Disease. IUBMB life, 2008, 60 (11), 724-728.
21. Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C. M.; Stefani, M., Inherent Toxicity of Aggregates Implies a Common Mechanism for Protein Misfolding Diseases. Nature, 2002, 416, 507-511.
22. Silveira, J. R.; Raymond, G. J.; Hughson, A. G.; Race, R. E.; Sim, V. L.; Hayes, S. F.; Caughey, B., The Most Infectious Prion Protein Particles. Nature, 2005, 437 (7056), 257-261.
23. Campioni, S.; Mannini, B.; Zampagni, M.; Pensalfini, A.; Parrini, C; Evangelisti, E.; Relini, A.; Stefani, M.; Dobson, C. M.; Cecchi, C; Chiti, F., A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol, 2010, 6 (2), 140-147.
24. Winner, B.; Jappelli, R.; Maji, S. K.; Desplats, P. A.; Boyer, L.; Aigner, S.; Hetzer, C; Loher, T.; Vilar, M.; Campioni, S.; Tzitzilonis, C; Soragni, A.; Jessberger, S.; Mira, H.; Consiglio, A.; Pham, E.; Masliah, E.; Gage, F. H.; Riek, R., In vivo demonstration that a-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA, 2011, 108 (10), 4194-4199.
25. Stroud, J. C; Liu, C; Teng, P. K.; Eisenberg, D., Toxic fibrillar oligomers of amyloid-p have cross-p structure. Proc. Natl. Acad. Sci. USA, 2012, 109 (20), 7717-7722.
26. Huang, C. C; Faber, P. W.; Persichetti, F.; Mittal, V.; Vonsattel, J. P.; MacDonald, M. E.; Gusella, J. F., Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell. Mol. Genet, 1998, 24 (4), 217-233.
27. Kazantsev, A.; Preisinger, E.; Dranovsky, A.; Goldgaber, D.; Housman, D., Insoluble Detergent-resistant Aggregates Form Between Pathological and Nonpathological Lengths of Polyglutamine in Mammalian Cells. Proc. Natl. Acad. Sci. USA, 1999, 96 (20), 11404-11409.
28. Steffan, J. S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y.-Z.; Gohler, H.; Wanker, E. E.; Bates, G. P.; Housman, D. E.; Thompson, L. M., The Huntington's Disease Protein Interacts with p53 and CREB-binding Protein and Represses Transcription. Proc. Natl. Acad. Sci. USA, 2000, 97 (12), 6763-6768.
29. Nucifora, F. C., Jr.; Sasaki, M.; Peters, M. F.; Huang, H.; Cooper, J. K.; Yamada, M.; Takahashi, H.; Tsuji, S.; Troncoso, J.; Dawson, V. L.; Dawson, T. M.; Ross, C. A., Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. Science, 2001, 291 (5512), 2423-2428.
30. Chai, Y.; Shao, J.; Miller, V. M.; Williams, A.; Paulson, H. L., Live-cell Imaging Reveals Divergent Intracellular Dynamics of Polyglutamine Disease Proteins and Supports a Sequestration Model of Pathogenesis. Proc. Natl. Acad. Sci. USA, 2002, 99 (14), 9310-9315.
31. Saudou, F.; Finkbeiner, S.; Devys, D.; Greenberg, M. E., Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions. Cell, 1998, 95 (1), 55-66.
32. Arrasate, M.; Mitra, S.; Schweitzer, E. S.; Segal, M. R.; Finkbeiner, S., Inclusion Body Formation Reduces Levels of Mutant Huntingtin and the Risk of Neuronal Death. Nature, 2004, 431 (7010), 805-810.
33. Bodner, R. A.; Outeiro, T. F.; Altmann, S.; Maxwell, M. M.; Cho, S. H.; Hyman, B. T.; McLean, P. J.; Young, A. B.; Housman, D. E.; Kazantsev, A. G., Pharmacological Promotion of Inclusion Formation: A Therapeutic Approach for Huntington's and Parkinson's Diseases. Proc. Natl. Acad. Sci. USA, 2006, 103 (11), 4246-4251.
34. Johnston, J. A.; Ward, C. L.; Kopito, R. R., Aggresomes: a cellular response to misfolded proteins. J. Cell Biol., 1998, 143 (7), 1883-1898.
35. Garcia-Mata, R.; Bebok, Z.; Sorscher, E. J.; Sztul, E. S., Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol., 1999, 146 (6), 1239-1254.
36. Kopito, R. R., Aggresomes, Inclusion Bodies and Protein Aggregation. Trends Cell Biol., 2000, 10 (12), 524.
37. Waelter, S.; Boeddrich, A.; Lurz, R.; Scherzinger, E.; Lueder, G.; Lehrach, H.; Wanker, E. E., Accumulation of Mutant Huntingtin Fragments in Aggresome-like Inclusion Bodies as a Result of Insufficient Protein Degradation. Mol. Biol. Cell, 2001, 12 (5), 1393-1407.
38. Muchowski, P. J.; Ning, K.; D'Souza-Schorey, C.; Fields, S., Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. USA, 2002, 99 (2), 727-732.
39. Wang, Y.; Meriin, A. B.; Zaarur, N.; Romanova, N. V.; Chernoff, Y. O.; Costello, C. E.; Sherman, M. Y., Abnormal Proteins can form Aggresome in Yeast: Aggresome-targeting Signals and Components of the Machinery. FASEB J., 2009, 23 (2), 451-463.
40. Rajan, R. S.; Illing, M. E.; Bence, N. F.; Kopito, R. R., Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl. Acad. Sci. USA, 2001, 98 (23), 13060-13065.
41. Kaganovich, D.; Kopito, R.; Frydman, J., Misfolded Proteins Partition Between Two Distinct Quality Control Compartments. Nature, 2008, 454 (7208), 1088-1095.
42. Matsumoto, G.; Kim, S.; Morimoto, R. I., Huntingtin and Mutant SOD1 Form Aggregate Structures with Distinct Molecular Properties in Human Cells. J. Biol. Chem., 2006, 281 (7), 4477-4485.
43. Taylor, J. P.; Tanaka, F.; Robitschek, J.; Sandoval, C. M.; Taye, A.; Markovic-Plese, S.; Fischbeck, K. H., Aggresomes Protect Cells by Enhancing the Degradation of Toxic Polyglutamine-containing Protein. Hum. Mol. Genet., 2003, 12 (7), 749-757.
44. Young, J. C.; Agashe, V. R.; Siegers, K.; Hartl, F. U., Pathways of Chaperone-Mediated Protein Folding in the Cytosol. Nat. Rev. Mol. Cell. Biol., 2004, 5 (10), 781-791.
45. Kaushik, S.; Cuervo, A. M., Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol., 2012, 22 (8), 407-417.
46. McClellan, A. J.; Tam, S.; Kaganovich, D.; Frydman, J., Protein quality control: chaperones culling corrupt conformations. Nature Cell Biol., 2005, 7 (8), 736-741.
47. Behrends, C.; Langer, C. A.; Boteva, R.; Bottcher, U. M.; Stemp, M. J.; Schaffar, G.; Rao, B. V.; Giese, A.; Kretzschmar, H.; Siegers, K.; Hartl, F. U., Chaperonin TRiC Promotes the Assembly of PolyQ Expansion Proteins into Nontoxic Oligomers. Mol. Cell, 2006, 23 (6), 887-897.
48. Wacker, J. L.; Zareie, M. H.; Fong, H.; Sarikaya, M.; Muchowski, P. J., Hsp70 and Hsp40 Attenuate Formation of Spherical and Annular Polyglutamine Oligomers by Partitioning Monomer. Nat. Struct. Mol. Biol., 2004, 11 (12), 1215-1222.
49. Warrick, J. M.; Chan, H. Y. E.; Gray-Board, G. L.; Chai, Y.; Paulson, H. L.; Bonini, N. M., Suppression of Polyglutamine-mediated Neurodegeneration in Drosophila by the Molecular Chaperone HSP70. Nat. Genet., 1999, 23 (4), 425.
50. Lotz, G. P.; Legleiter, J.; Aron, R.; Mitchell, E. J.; Huang, S. Y.; Ng, C.; Glabe, C.; Thompson, L. M.; Muchowski, P. J., Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle. J. Biol. Chem., 2010, 285 (49), 38183-38193.
51. Olshina, M. A.; Angley, L. M.; Ramdzan, Y. M.; Tang, J.; Bailey, M. F.; Hill, A. F.; Hatters, D. M., Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool. J. Biol. Chem., 2010, 285 (28), 21807-21816.
52. Kim, S.; Nollen, E. A. A.; Kitagawa, K.; Bindokas, V. P.; Morimoto, R. I., Polyglutamine Protein Aggregates Are Dynamic. Nat. Cell Biol., 2002, 4 (10), 826-831.
53. Zhang, X.; Qian, S.-B., Chaperone-mediated hierarchical control in targeting misfolded proteins to aggresomes. Mol. Biol. Cell, 2011, 22 (18), 3277-3288.
54. Jana, N. R.; Tanaka, M.; Wang, G.-H.; Nukina, N., Polyglutamine Length-dependent Interaction of Hsp40 and Hsp70 Family Chaperones with Truncated N-terminal Huntingtin: their Role in Suppression of Aggregation and Cellular Toxicity. Hum. Mol. Genet., 2000, 9 (13), 2009-2018.
55. Zhou, H.; Li, S.-H.; Li, X.-J., Chaperone Suppression of Cellular Toxicity of Huntingtin Is Independent of Polyglutamine Aggregation. J. Biol. Chem., 2001, 276 (51), 48417-48424.
56. Rujano, M. A.; Kampinga, H. H.; Salomons, F. A., Modulation of Polyglutamine Inclusion Formation by the Hsp70 Chaperone Machine. Exp. Cell. Res., 2007, 313 (16), 3568-3578.
57. Wacker, J. L.; Huang, S.-Y.; Steele, A. D.; Aron, R.; Lotz, G. P.; Nguyen, Q.; Giorgini, F.; Roberson, E. D.; Lindquist, S.; Masliah, E.; Muchowski, P. J., Loss of Hsp70 Exacerbates Pathogenesis But Not Levels of Fibrillar Aggregates in a Mouse Model of Huntington's Disease. J. Neurosci., 2009, 29 (28), 9104-9114.
58. Cummings, C. J.; Sun, Y.; Opal, P.; Antalffy, B.; Mestril, R.; Orr, H. T.; Dillmann, W. H.; Zoghbi, H. Y., Over-expression of Inducible HSP70 Chaperone Suppresses Neuropathology and Improves Motor Function in SCA1 Mice. Hum. Mol. Genet., 2001, 10 (14), 1511-1518.
59. Muchowski, P. J.; Schaffar, G.; Sittler, A.; Wanker, E. E.; Hayer-Hartl, M. K.; Hartl, F. U., Hsp70 and Hsp40 Chaperones Can Inhibit Self-assembly of Polyglutamine Proteins into Amyloid-like Fibrils. Proc. Natl. Acad. Sci. USA, 2000, 97 (14), 7841-7846.
60. Chafekar, S. M.; Duennwald, M. L., Impaired Heat Shock Response in Cells Expressing Full-Length Polyglutamine-Expanded Huntingtin. PLoS ONE, 2012, 7 (5), e37929.
61. Gidalevitz, T.; Ben-Zvi, A.; Ho, K. H.; Brignull, H. R.; Morimoto, R. I., Progressive Disruption of Cellular Protein Folding in Models of Polyglutamine Diseases. Science, 2006, 311 (5766), 1471-1474.
62. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W., Adapting Proteostasis for Disease Intervention. Science, 2008, 319 (5865), 916-919.
63. Ko, J.; Ou, S.; Patterson, P. H., New Anti-huntingtin Monoclonal Antibodies: Implications for Huntingtin Conformation and its Binding Proteins. Brain Res. Bull., 2001, 56 (3-4), 319-329.
64. Li, P.; Huey-Tubman, K. E.; Gao, T.; Li, X.; West, A. P.; Bennett, M. J.; Bjorkman, P. J., The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat. Struct. Mol. Biol., 2007, 14 (5), 381-387.
65. Weiss, A.; Abramowski, D.; Bibel, M.; Bodner, R.; Chopra, V.; DiFiglia, M.; Fox, J.; Kegel, K.; Klein, C.; Grueninger, S.; Hersch, S.; Housman, D.; Régulier, E.; Rosas, H. D.; Stefani, M.; Zeitlin, S.; Bilbe, G.; Paganetti, P., Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. Anal. Biochem., 2009, 395 (1), 8-15.
66. Semmelroth, M.; Zivanovic, A.; Abramowski, D.; Smith, D.; Lotz, Gregor P.; Bates, Gillian P.; Weiss, A., TR-FRET-Based Duplex Immunoassay Reveals an Inverse Correlation of Soluble and Aggregated Mutant huntingtin in Huntington's Disease. Chem. Biol., 2012, 19 (2), 264-275.
67. Lecerf, J.-M.; Shirley, T. L.; Zhu, Q.; Kazantsev, A.; Amersdorfer, P.; Housman, D. E.; Messer, A.; Huston, J. S., Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2001, 98 (8), 4764-4769.
68. Colby, D. W.; Chu, Y.; Cassady, J. P.; Duennwald, M.; Zazulak, H.; Webster, J. M.; Messer, A.; Lindquist, S.; Ingram, V. M.; Wittrup, K. D., Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. USA, 2004, 101 (51), 17616-17621.
69. Southwell, A. L.; Khoshnan, A.; Dunn, D. E.; Bugg, C. W.; Lo, D. C.; Patterson, P. H., Intrabodies Binding the Proline-Rich Domains of Mutant Huntingtin Increase Its Turnover and Reduce Neurotoxicity. J. Neurosci., 2008, 28 (36), 9013-9020.
70. Wang, C.-E.; Zhou, H.; McGuire, J. R.; Cerullo, V.; Lee, B.; Li, S.-H.; Li, X.-J., Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol., 2008, 181 (5), 803-816.
71. Southwell, A. L.; Ko, J.; Patterson, P. H., Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease. J. Neurosci., 2009, 29 (43), 13589-13602.
72. Snyder-Keller, A.; McLear, J. A.; Hathorn, T.; Messer, A., Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J. Neuropathol. Exp. Neurol., 2010, 69 (10), 1078-1085.
73. Butler, D. C.; Messer, A., Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments. PLoS ONE, 2011, 6 (12), e29199.
74. Kvam, E.; Nannenga, B. L.; Wang, M. S.; Jia, Z.; Sierks, M. R.; Messer, A., Conformational Targeting of Fibrillar Polyglutamine Proteins in Live Cells Escalates Aggregation and Cytotoxicity. PLoS ONE, 2009, 4 (5), e5727.
75. Barkhordarian, H.; Emadi, S.; Schulz, P.; Sierks, M. R., Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng. Des. Sel., 2006, 19 (11), 497-502.
76. Díaz-Hernández, M.; Moreno-Herrero, F.; Gómez-Ramos, P.; Morán, M. A.; Ferrer, I.; Baró, A. M.; Avila, J.; Hernández, F.; Lucas, J. J., Biochemical, Ultrastructural, and Reversibility Studies on Huntingtin Filaments Isolated from Mouse and Human Brain. J. Neurosci., 2004, 24 (42), 9361-9371.
77. Legleiter, J.; Mitchell, E.; Lotz, G. P.; Sapp, E.; Ng, C.; DiFiglia, M.; Thompson, L. M.; Muchowski, P. J., Mutant Huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J. Biol. Chem., 2010, 285 (19), 14777-14790.
78. Scherzinger, E.; Lurz, R.; Turmaine, M.; Mangiarini, L.; Hollenbach, B.; Hasenbank, R.; Bates, G. P.; Davies, S. W.; Lehrach, H.; Wanker, E. E., Huntingtin-encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In vitro and In vivo. Cell, 1997, 90 (3), 549-558.
79. Andreas, W.; Corinna, K.; Ben, W.; Kirupa, S.; Miriam, B.; Etienne, R.; Gillian, P. B.; Paolo, P., Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J. Neurochem., 2008, 104 (3), 846-858.
80. Hazeki, N.; Tsukamoto, T.; Yazawa, I.; Koyama, M.; Hattori, S.; Someki, I.; Iwatsubo, T.; Nakamura, K.; Goto, J.; Kanazawa, I., Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine. Biochem. Biophys. Res. Commun., 2002, 294 (2), 429-440.
81. Nekooki-Machida, Y.; Kurosawa, M.; Nukina, N.; Ito, K.; Oda, T.; Tanaka, M., Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl. Acad. Sci. U S A, 2009, 106 (24), 9679-9684.
82. Tanaka, M.; Chien, P.; Naber, N.; Cooke, R.; Weissman, J. S., Conformational variations in an infectious protein determine prion strain differences. Nature, 2004, 428 (6980), 323-328.
83. Petkova, A. T.; Leapman, R. D.; Guo, Z.; Yau, W.-M.; Mattson, M. P.; Tycko, R., Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils. Science, 2005, 307 (5707), 262-265.
84. Griffin, M. D. W.; Mok, M. L. Y.; Wilson, L. M.; Pham, C. L. L.; Waddington, L. J.; Perugini, M. A.; Howlett, G. J., Phospholipid Interaction Induces Molecular-level Polymorphism in Apolipoprotein C-II Amyloid Fibrils via Alternative Assembly Pathways. J. Mol. Biol, 2008, 375 (1), 240-256.
85. Gosal, W. S.; Morten, I. J.; Hewitt, E. W.; Smith, D. A.; Thomson, N. H.; Radford, S. E., Competing pathways determine fibril morphology in the self-assembly of β2-microglobulin into amyloid. J. Mol. Biol., 2005, 351 (4), 850-864.
86. Miller, J.; Arrasate, M.; Brooks, E.; Libeu, C. P.; Legleiter, J.; Hatters, D.; Curtis, J.; Cheung, K.; Krishnan, P.; Mitra, S.; Widjaja, K.; Shaby, B. A.; Lotz, G. P.; Newhouse, Y.; Mitchell, E. J.; Osmand, A.; Gray, M.; Thulasiramin, V.; Saudou, F.; Segal, M.; Yang, X. W.; Masliah, E.; Thompson, L. M.; Muchowski, P. J.; Weisgraber, K. H.; Finkbeiner, S., Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol, 2011, 7 (12), 925-934.
87. Martindale, D.; Hackam, A.; Wieczorek, A.; Ellerby, L.; Wellington, C; McCutcheon, K.; Singaraja, R.; Kazemi-Esfarjani, P.; Devon, R.; Kim, S. U.; Bredesen, D. E.; Tufaro, F.; Hayden, M. R., Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet., 1998, 18 (2), 150-154.
88. Sathasivam, K.; Lane, A.; Legleiter, J.; Warley, A.; Woodman, B.; Finkbeiner, S.; Paganetti, P.; Muchowski, P. J.; Wilson, S.; Bates, G. P., Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum. Mol. Genet., 2010, 19 (1), 65-78.
89. Lane, A.; Stanley, C. J.; Dealler, S.; Wilson, S. M., Polymeric Ligands with Specificity for Aggregated Prion Proteins. Clin. Chem., 2003, 49 (10), 1774-1775.
90. Bennett, M. J.; Huey-Tubman, K. E.; Herr, A. B.; West, A. P., Jr.; Ross, S. A.; Bjorkman, P. J., A Linear Lattice model for Polyglutamine in CAG-expansion Diseases. Proc. Natl. Acad. Sci. USA, 2002, 99 (18), 11634-11639.
91. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S. W.; Bates, G. P., Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice. Cell, 1996, 87 (3), 493-506.
92. Schilling, G.; Becher, M. W.; Sharp, A. H.; Jinnah, H. A.; Duan, K.; Kotzuk, J. A.; Slunt, H. H.; Ratovitski, T.; Cooper, J. K.; Jenkins, N. A.; Copeland, N. G.; Price, D. L.; Ross, C. A.; Borchelt, D. R., Intranuclear Inclusions and Neuritic Aggregates in Transgenic Mice Expressing a Mutant N-Terminal Fragment of Huntingtin. Hum. Mol. Genet., 1999, 8 (3), 397-407.
93. Slow, E. J.; Graham, R. K.; Osmand, A. P.; Devon, R. S.; Lu, G.; Deng, Y.; Pearson, J.; Vaid, K.; Bissada, N.; Wetzel, R.; Leavitt, B. R.; Hayden, M. R., Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA, 2005, 102 (32), 11402-11407.
94. Ratovitski, T.; Gucek, M.; Jiang, H.; Chighladze, E.; Waldron, E.; D'Ambola, J.; Hou, Z.; Liang, Y.; Poirier, M. A.; Hirschhorn, R. R.; Graham, R.; Hayden, M. R.; Cole, R. N.; Ross, C. A., Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells. J. Biol. Chem., 2009, 284 (16), 10855-10867.
95. Nucifora, L. G.; Burke, K. A.; Feng, X.; Arbez, N.; Zhu, S.; Miller, J.; Yang, G.; Ratovitski, T.; Delannoy, M.; Muchowski, P. J.; Finkbeiner, S.; Legleiter, J; Ross, C. A.; Poirier, M. A., Identification of Novel Potentially Toxic Oligomers Formed in vitro from Mammalian-derived Expanded huntingtin Exon-1 Protein. J. Biol. Chem., 2012, 287 (19), 16017-16028.
96. Tebbenkamp, A. T. N.; Swing, D.; Tessarollo, L.; Borchelt, D. R., Premature death and neurologic abnormalities in transgenic mice expressing a mutant huntingtin exon-2 fragment. Hum. Mol. Genet., 2011, 20 (8), 1633-1642.
97. Landles, C.; Sathasivam, K.; Weiss, A.; Woodman, B.; Moffitt, H.; Finkbeiner, S.; Sun, B.; Gafni, J.; Ellerby, L. M.; Trottier, Y.; Richards, W. G.; Osmand, A.; Paganetti, P.; Bates, G. P., Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem., 2010, 285 (12), 8808-8823.
98. Lunkes, A.; Lindenberg, K. S.; Ben-Hai, L.; Weber, C.; Devys, D.; Landwehrmeyer, G. B.; Mandel, J.-L.; Trottier, Y., Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions. Mol. Cell, 2002, 10 (2), 259-269.
99. Graham, R. K.; Deng, Y.; Slow, E. J.; Haigh, B.N.; Roy, S.; Wellington, C. L.; Leavitt, B. R.; Raymond, L. A.; Nicholson, D. W.; Hayden, M. R., Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 2006, 125 (6), 1179-1191.
100. Waldron-Roby, E.; Ratovitski, T.; Wang, X.; Jiang, M.; Watkin, E.; Arbez, N.; Graham, R. K.; Hayden, M. R.; Hou, Z.; Mori, S.; Swing, D.; Pletnikov, M.; Duan, W.; Tessarollo, L.; Ross, C. A., Transgenic Mouse Model Expressing the Caspase 6 Fragment of Mutant Huntingtin. J. Neurosci., 2012, 32 (1), 183-193.
101. Tebbenkamp, A. T. N.; Green, C.; Xu, G.; Denovan-Wright, E. M.; Rising, A. C.; Fromholt, S. E.; Brown, H. H.; Swing, D.; Mandel, R. J.; Tessarollo, L.; Borchelt, D. R., Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum. Mol. Genet., 2011, 20 (14), 2770-2782.
102. Duennwald, M. L.; Jagadish, S.; Muchowski, P. J.; Lindquist, S., Flanking Sequences Profoundly Alter Polyglutamine Toxicity in Yeast. Proc. Natl. Acad. Sci. USA, 2006, 103 (29), 11045-11050.
103. Duennwald, M. L.; Jagadish, S.; Giorgini, F.; Muchowski, P. J.; Lindquist, S., A network of protein interactions determines polyglutamine toxicity. Proc. Natl. Acad. Sci. USA, 2006, 103 (29), 11051-11056.
104. Li, S. S., Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem. J., 2005, 390 (Pt 3), 641-653.
105. Sittler, A.; Wälter, S.; Wedemeyer, N.; Hasenbank, R.; Scherzinger, E.; Eickhoff, H.; Bates, G. P.; Lehrach, H.; Wanker, E. E., SH3GL3 Associates with the Huntingtin Exon 1 Protein and Promotes the Formation of Polygln-Containing Protein Aggregates. Mol. Cell, 1998, 2 (4), 427-436.
106. Davranche, A.; Aviolat, H.; Zeder-Lutz, G.; Busso, D.; Altschuh, D.; Trottier, Y.; Klein, F. A. C., Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. Hum. Mol. Genet., 2011, 20 (14), 2795-2806.
107. Khoshnan, A.; Ko, J.; Patterson, P. H., Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA, 2002, 99 (2), 1002-1007.
108. Mukai, H.; Isagawa, T.; Goyama, E.; Tanaka, S.; Bence, N. F.; Tamura, A.; Ono, Y.; Kopito, R. R., Formation of Morphologically Similar Globular Aggregates From Diverse Aggregation-prone Proteins in Mammalian Cells. Proc. Natl. Acad. Sci. USA, 2005, 102 (31), 10887-10892.
109. Takahashi, Y.; Okamoto, Y.; Popiel, H. A.; Fujikake, N.; Toda, T.; Kinjo, M.; Nagai, Y., Detection of Polyglutamine Protein Oligomers in Cells by Fluorescence Correlation Spectroscopy. J. Biol. Chem., 2007, 282 (33), 24039-24048.
110. Takahashi, T.; Kikuchi, S.; Katada, S.; Nagai, Y.; Nishizawa, M.; Onodera, O., Soluble Polyglutamine Oligomers Formed Prior to Inclusion Body Formation are Cytotoxic. Hum. Mol. Genet., 2007, 17 (3), 345-346.
111. Ossato, G.; Digman, M. A.; Aiken, C.; Lukacsovich, T.; Marsh, J. L.; Gratton, E., A Two-Step Path to Inclusion Formation of Huntingtin Peptides Revealed by Number and Brightness Analysis. Biophys. J., 2010, 98 (12), 3078-3085.
112. Lajoie, P.; Snapp, E. L., Formation and Toxicity of Soluble Polyglutamine Oligomers in Living Cells. PLoS ONE, 2011, 5 (12), e15245.
113. Hu, C.-D.; Kerppola, T. K., Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis. Nat. Biotech, 2003, 21 (5), 539-545.
114. Kotliarova, S.; Jana, N. R.; Sakamoto, N.; Kurosawa, M.; Miyazaki, H.; Nekooki, M.; Doi, H.; Machida, Y.; Wong, H. K.; Suzuki, T.; Uchikawa, C.; Kotliarov, Y.; Uchida, K.; Nagao, Y.; Nagaoka, U.; Tamaoka, A.; Oyanagi, K.; Oyama, F.; Nukina, N., Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J. Neurochem., 2005, 93 (3), 641-653.
115. Jackson, G. R.; Salecker, I.; Dong, X.; Yao, X.; Arnheim, N.; Faber, P. W.; MacDonald, M. E.; Zipursky, S. L., Polyglutamine-Expanded Human Huntingtin Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons. Neuron, 1998, 21 (3), 633-642.
116. Brignull, H. R.; Moore, F. E.; Tang, S. J.; Morimoto, R. I., Polyglutamine Proteins at the Pathogenic Threshold Display Neuron-Specific Aggregation in a Pan-Neuronal Caenorhabditis elegans Model. J. Neurosci., 2006, 26 (29), 7597-7606.
117. Ramdzan, Y. M.; Nisbet, R. M.; Miller, J.; Finkbeiner, S.; Hill, A. F.; Hatters, D. M., Conformation sensors that distinguish monomeric proteins from oligomers in live cells. Chem. Biol, 2010, 17 (4), 371-379.
118. Ramdzan, Y. M.; Polling, S.; Chia, C. P. Z.; Ng, I. H. W.; Ormsby, A. R.; Croft, N. P.; Purcell, A. W.; Bogoyevitch, M. A.; Ng, D. C. H.; Gleeson, P. A.; Hatters, D. M., Tracking protein aggregation and mislocalization in cells with flow cytometry. Nat. Meth., 2012, 9 (5), 467-470.
119. Poirier, M. A.; Li, H.; Macosko, J.; Cai, S.; Amzel, M.; Ross, C. A., Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization. J. Biol. Chem., 2002, 277 (43), 41032-41037.
120. Masino, L.; Kelly, G.; Leonard, K.; Trottier, Y.; Pastore, A., Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett., 2002, 513 (2-3), 267-272.
121. Crick, S. L.; Jayaraman, M.; Frieden, C.; Wetzel, R.; Pappu, R. V., Fluorescence Correlation Spectroscopy Shows That Monomeric Polyglutamine Molecules Form Collapsed Structures in Aqueous Solutions. Proc. Natl. Acad. Sci. USA, 2006, 103 (45), 16764-16769.
122. Wang, X.; Vitalis, A.; Wyczalkowski, M. A.; Pappu, R. V., Characterizing the conformational ensemble of monomeric polyglutamine. Proteins, 2006, 63 (2), 297-311.
123. Singh, V. R.; Lapidus, L. J., The Intrinsic Stiffness of Polyglutamine Peptides. J. Phys. Chem. B, 2008, 112 (42), 13172-13176.
124. Dougan, L.; Li, J.; Badilla, C. L.; Berne, B. J.; Fernandez, J. M., Single Homopolypeptide Chains Collapse into Mechanically Rigid Conformations. Proc. Natl. Acad. Sci. USA, 2009, 106 (31), 12605-12610.
125. Kim, M. W.; Chelliah, Y.; Kim, S. W.; Otwinowski, Z.; Bezprozvanny, I., Secondary Structure of Huntingtin Amino-Terminal Region. Structure, 2009, 17 (9), 1205-1212.
126. Walters, R. H.; Murphy, R. M., Examining Polyglutamine Peptide Length: A Connection between Collapsed Conformations and Increased Aggregation. J. Mol. Biol., 2009, 393 (4), 978-992.
127. Bennett, E. J.; Shaler, T. A.; Woodman, B.; Ryu, K.-Y.; Zaitseva, T. S.; Becker, C. H.; Bates, G. P.; Schulman, H.; Kopito, R. R., Global Changes to the Ubiquitin System in Huntington's Disease. Nature, 2007, 448 (7154), 704.
128. Venkatraman, P.; Wetzel, R.; Tanaka, M.; Nukina, N.; Goldberg, A. L., Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell, 2004, 14 (1), 95-104.
129. Nagai, Y.; Inui, T.; Popiel, H. A.; Fujikake, N.; Hasegawa, K.; Urade, Y.; Goto, Y.; Naiki, H.; Toda, T., A Toxic Monomeric Conformer of the Polyglutamine Protein. Nat. Struct. Mol. Biol., 2007, 14 (4), 332-340.
130. Schaffar, G.; Breuer, P.; Boteva, R.; Behrends, C.; Tzvetkov, N.; Strippel, N.; Sakahira, H.; Siegers, K.; Hayer-Hartl, M.; Hartl, F. U., Cellular Toxicity of Polyglutamine Expansion Proteins: Mechanism of Transcription Factor Deactivation. Mol. Cell, 2004, 15 (1), 95-105.
131. Peters-Libeu, C.; Miller, J.; Rutenber, E.; Newhouse, Y.; Krishnan, P.; Cheung, K.; Hatters, D.; Brooks, E.; Widjaja, K.; Tran, T.; Mitra, S.; Arrasate, M.; Mosquera, L. A.; Taylor, D.; Weisgraber, K. H.; Finkbeiner, S., Disease-Associated Polyglutamine Stretches in Monomeric Huntingtin Adopt a Compact Structure. J. Mol. Biol, 2012, 421(4-5), 587-600.
132. Zhang, Q. C; Yeh, T.-L.; Leyva, A.; Frank, L. G.; Miller, J.; Kim, Y. E.; Langen, R.; Finkbeiner, S.; Amzel, M. L.; Ross, C. A.; Poirier, M. A., A Compact β Model of huntingtin Toxicity. J. Biol. Chem., 2011, 286 (10), 8188-8196.
133. Thakur, A. K.; Wetzel, R., Mutational Analysis of the Structural Organization of Polyglutamine Aggregates. Proc. Natl. Acad. Sci. USA, 2002, 99 (26), 17014-17019.
134. Poirier, M. A.; Jiang, H.; Ross, C. A., A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. Hum. Mol. Genet, 2005, 14 (6), 765-774.
135. van Ham, T. J.; Holmberg, M. A.; van der Goot, A. T.; Teuling, E.; Garcia-Arencibia, M.; Kim, H.-E.; Du, D.; Thijssen, K. L.; Wiersma, M.; Burggraaff, R.; van Bergeijk, P.; van Rheenen, J.; Jerre van Veluw, G.; Hofstra, R. M. W.; Rubinsztein, D. C; Nollen, E. A. A., Identification of MOAG-4/SERF as a Regulator of Age-Related Proteotoxicity. Cell, 2010, 142 (4), 601-612.
136. Atwal, R. S.; Xia, J.; Pinchev, D.; Taylor, J.; Epand, R. M.; Truant, R., Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet, 2007, 16 (21), 2600-2615.
137. Rockabrand, E.; Slepko, N.; Pantalone, A.; Nukala, V. N.; Kazantsev, A.; Marsh, J. L.; Sullivan, P. G.; Steffan, J. S.; Sensi, S. L.; Thompson, L. M., The First 17 Amino Acids of Huntingtin Modulate its Sub-cellular Localization, Aggregation and Effects on Calcium Homeostasis. Hum. Mol. Genet, 2007, 16 (1), 61-77.
138. Sivanandam, V. N.; Jayaraman, M.; Hoop, C. L.; Kodali, R.; Wetzel, R.; van der Wel, P. C. A., The Aggregation-Enhancing Huntingtin N-Terminus Is Helical in Amyloid Fibrils. J. Am. Chem. Soc, 2011, 133 (12), 4558-4566.
139. Jayaraman, M.; Kodali, R.; Sahoo, B.; Thakur, A. K.; Mayasundari, A.; Mishra, R.; Peterson, C. B.; Wetzel, R., Slow Amyloid Nucleation via a-Helix-Rich Oligomeric Intermediates in Short Polyglutamine-Containing Huntingtin Fragments. J. Mol. Biol, 2012, 415 (5), 881-899.
140. Hatters, D. M.; Howlett, G. J., The Structural Basis for Amyloid Formation by Plasma Apolipoproteins: A Review. Eur. Biophys. J., 2002, 31, 2-8.
141. Hatters, D. M.; Zhong, N.; Rutenber, E.; Weisgraber, K. H., Amino-terminal Domain Stability Mediates Apolipoprotein E Aggregation into Neurotoxic Fibrils. J. Mol. Biol, 2006, 361 (5), 932-944.
142. Steffan, J. S.; Agrawal, N.; Pallos, J.; Rockabrand, E.; Trotman, L. C; Slepko, N.; Illes, K.; Lukacsovich, T.; Zhu, Y. Z.; Cattaneo, E.; Pandolfi, P. P.; Thompson, L. M.; Marsh, J. L., SUMO modification of Huntingtin and Huntington's disease pathology. Science, 2004, 304 (5667), 100-104.
143. Aiken, C. T.; Steffan, J. S.; Guerrero, C. M.; Khashwji, H.; Lukacsovich, T.; Simmons, D.; Purcell, J. M.; Menhaji, K.; Zhu, Y. Z.; Green, K.; Laferla, F.; Huang, L.; Thompson, L. M.; Marsh, J. L., Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J. Biol. Chem., 2009, 284 (43), 29427-29436.
144. Van Damme, P.; Arnesen, T.; Gevaert, K., Protein alpha-N-acetylation studied by N-terminomics. FEBS J., 2011, 278 (20), 3822-3834.
145. Kang, L.; Moriarty, G. M.; Woods, L. A.; Ashcroft, A. E.; Radford, S. E.; Baum, J., N-terminal acetylation of a-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci., 2012, 21 (7), 911-917.
146. Thompson, L. M.; Aiken, C. T.; Kaltenbach, L. S.; Agrawal, N.; Illes, K.; Khoshnan, A.; Martinez-Vincente, M.; Arrasate, M.; O'Rourke, J. G.; Khashwji, H.; Lukacsovich, T.; Zhu, Y. Z.; Lau, A. L.; Massey, A.; Hayden, M. R.; Zeitlin, S. O.; Finkbeiner, S.; Green, K. N.; LaFerla, F. M.; Bates, G.; Huang, L.; Patterson, P. H.; Lo, D. C; Cuervo, A. M.; Marsh, J. L.; Steffan, J. S., IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol, 2009, 187 (7), 1083-1099.
147. Garber, K., Amyloid disease drug approved. Nat. Biotech, 2012, 30 (2), 121-121.
148. Narhi, L. O.; Schmit, J.; Bechtold-Peters, K.; Sharma, D., Classification of protein aggregates. J. Pharm. Sci., 2012, 101 (2), 493-498.
149. Doumanis, J.; Wada, K.; Kino, Y.; Moore, A. W.; Nukina, N., RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation. PLoS ONE, 2009, 4 (9), e7275.
150. Zhang, S.; Binari, R.; Zhou, R.; Perrimon, N., A Genomewide RNA Interference Screen for Modifiers of Aggregates Formation by Mutant Huntingtin in Drosophila. Genetics, 2010, 184 (4), 1165-1179.
151. Kaltenbach, L. S.; Romero, E.; Becklin, R. R.; Chettier, R.; Bell, R.; Phansalkar, A.; Strand, A.; Torcassi, C; Savage, J.; Hurlburt, A.; Cha, G. H.; Ukani, L.; Chepanoske, C. L.; Zhen, Y.; Sahasrabudhe, S.; Olson, J.; Kurschner, C; Ellerby, L. M.; Peltier, J. M.; Botas, J.; Hughes, R. E., Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genetics, 2007, 3 (5), e82.
152. Fuentealba, R. A.; Marasa, J.; Diamond, M. I.; Piwnica-Worms, D.; Weihl, C. C, An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum. Mol. Genet, 2012, 21 (3), 664-680.
153. Trottier, Y.; Lutz, Y.; Stevanin, G.; Imbert, G.; Devys, D.; Cancel, G.; Saudou, F.; Weber, C; David, G.; Tora, L.; et al., Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature, 1995, 378 (6555), 403-406.
154. Wang, J.; Wang, C. E.; Orr, A.; Tydlacka, S.; Li, S. H.; Li, X. J., Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol, 2008, 180 (6), 1177-1189.